ClinicalTrials.gg
CompletedNCT02086097DTPEPUpdated May 7, 2014

Dexketoprofen Trometamol in Postoperative Endodontic Pain

A Phase 4 interventional study of Dexketoprofen trometamol and Ibuprofen in Irreversible Pulpitis, sponsored by Daniel Chavarría Bolaños. Completed at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-07.

Sponsored by Daniel Chavarría Bolaños · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the analgesic efficacy of multiple doses of Dexketoprofen Trometamol 25 mg on postoperative pain following emergency endodontic treatment in teeth with irreversible pulpitis, using as control Ibuprofen 600 mg and a placebo group.

Hypothesis:

Dexketoprofen trometamol when administered in multiple doses produces a greater effect to control postoperative pain after treating symptomatic irreversible pulpitis; in patients undergoing pulpotomy as an emergency procedure

Read the detailed description

Pain management is an integral part of Endodontics, according to previously published results, pulp therapy and endodontic treatment induce postoperative pain more frequently than other dental procedures.

The prevalence of postoperative pain has been reported in 3-58% of cases, a positive association has been demonstrated between postoperative pain and the presence of apprehension and preoperative pain.

Although the incidence of moderate pain decreases within 1 day and substantially to minimal levels in 7 days after the endodontic treatment, severe postoperative pain occurs during the first 24 h.

Some drugs can prevent the production of inflammatory mediators involved in producing pain, such as prostaglandins.

Prostaglandin tissue levels are associated with patient reports of pain, and therefore, nonsteroidal anti-inflammatory drugs (NSAID's) may be key drugs for inflammatory pain abatement.

NSAIDs are widely available, and they have been reported to be effective in managing endodontic pain.

Ibuprofen is one of the most frequently used NSAIDs for control of postoperative pain associated with root canal treatment, and it has good efficacy and safety.

However an alternative treatment is Dexketoprofen Trometamol, a non-selective nonsteroidal anti-inflammatory drug, and a single isomer (S(+)-enantiomer) of ketoprofen formulated as trometamol salt. Dexketoprofen trometamol has been demonstrated to be effective in the treatment of acute pain.

The purpose of the study is assess the analgesic efficacy of multiple doses of Dexketoprofen Trometamol 25 mg on postoperative pain following emergency endodontic treatment in teeth with irreversible pulpitis This study was designed as a double-blind, randomised, placebo-controlled clinical trial. Following the guidelines suggested by CONSORT group for planning and reporting clinical trials. The ethics committee of the faculty of Dentistry approved the study design. All of the subjects will be informed of the possible risk of endodontic therapy and experimental treatments and will sign institutionally approved consents forms.

In total, 87 patients will be included in this study. The simple size calculation was performed with a type error of 0.05 and statistical power of 80% on the basis of report of the analgesic efficacy of Dexketoprofen Trometamol 25 mg vs Ibuprofen 600 mg after their administration in patients subject to oral surgery.

All of the subjects voluntarily will presented at the postgraduate endodontics clinic of the Faculty of Dentistry at San Luis Potosí University. The select subjects will have a diagnosis of symptomatic irreversible pulpitis.

Pain will be scored using numerical rating scale, this is a 11 point scale where the end points are the extremes of no pain and pain as bad as it could be, or worst pain. Accordingly, no pain corresponded with 0, mild pain with 1-3, moderate pain with 4-6, and severe pain 7 and above.7 After the endodontic emergency treatment, patients will be randomly divided into three groups of 27 patients each. A control group will receive multiple doses of placebo and 2 experimental groups receive multiple dose of ibuprofen (600 mg) and Dexketoprofen trometamol (25 mg). The first dose of medication is given once the procedure is completed, the following doses will be taken every 8 hours to cover a total of 24 hours.

Patients will be monitored to assess the therapeutic effect at different time intervals, 1,8,16,24,48 and 72 hours using numerical rating scale.

If the analgesic efficacy is not achieved Supradol (Ketorolac 30 mg) or Zaldiar (Paracetamol 325mg/Tramadol 37.5 mg) will be taken as rescue medication.Any adverse events or symptoms will be recorded.

Statistics Normal distribution will be tested by the Student's-t test or mann-whitney U test. A non -parametric chi-squared test was performed to identify statistically significant differences between the groups; the level of significance was set at p\<0.05.

02

Conditions studied

  • Irreversible Pulpitis

Browse trials for

Keywords

  • pain
  • symptomatic irreversible pulpitis
  • postoperative dental pain
03

In context

Pain

2,450 studies on the registry are indexed under Pain; 945 are open to participants now.

This study's enrollment of 90 is above the median of 70 across 2,101 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Daniel Chavarría Bolaños is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 years and older with moderate-to-severe dental pain assessed by numerical rating scale (NRS) associated with irreversible pulpitis.

Exclusion criteria

Exclusion Criteria:

    • Female pregnant or breastfeeding

      • Used pain relievers or anti-inflammatory drugs within 24 hours preceding emergency endodontic treatment
      • Have any significant medical condition
      • Taking any medications for anxiety, depression or schizophrenia
      • Have a history of hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    dexketoprofen trometamol

    Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed

    Drug: Dexketoprofen trometamol

  • Active comparator
    IBUPROFEN

    Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed

    Drug: Ibuprofen

  • Placebo comparator
    PLACEBO

    4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed

    Drug: PLACEBO

Interventions

  • 25m of dexketoprofen (oral intake) every 8 hours

    Also known as: Miracox (Stein Labs), CODE: 00176101

  • 600 mg of Ibuprofen (Oral Intake) every 8 hours

    Also known as: Ibuprofen Stein, CODE: 00065104

  • DrugPLACEBO

    INACTIVE SUGAR PILLS

    Also known as: PLAC

06

What researchers measure

Primary outcomes

  1. post operative pain measurement in symptomatic irreversible pulpitis, after multiple doses of dexketoprofen trometamol

    Using a visual analogue scale, each patient is asked to inform the researcher team about postoperative pain levels at 1, 8, 16, 24, 48 and 72 hours after pulpotomy procedure as emergency clinical manage of endodontic pain in irreversible pulpitis cases. Patients will be asked to take multiple doses of either Dexketoprofen Trometamol 25mg, Ibuprofen 600mg or placebo pills. Also, aspects like local anesthetic effect duration and local/systemic side effects will be monitored. Each patient will have a personal file to record the information during each period (1, 8, 16, 24, 48 and 72 hours )

    Time frame: 1 observation after 72 hours of emergency clinical procedure (Pulpotomy) for pain management

Secondary outcomes

  1. Duration of the activity of the analgesic treatment

    The duration of the effect of each drug will be recorded

    Time frame: observation periods of 1, 8, 16, 24, 48 AND 72 hours

07

Study locations

1 site
  • Endodontics Master Degree program, Dentistry Faculty, San Luis Potosi University
    San Luis Potosí City, San Luis Potosí 78290, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2014
First posted
Mar 13, 2014
Start
Aug 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
May 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02086097
Lead sponsor
Daniel Chavarría Bolaños
Responsible party
Daniel Chavarría Bolaños (Basic Sciences Laboratory, Dentistry School, Universidad Autonoma de San Luis Potosí) — Sponsor-investigator
First posted
Mar 13, 2014
Start date
Aug 2013
Primary completion
Apr 2014
Completion
Apr 2014
Last update
May 7, 2014

Study contacts

Gisela Rodríguez, DDS
principal investigator · Universidad Autonoma San Luis Potosi
Amaury J Pozos-Guillen, PhD
study chair · Universidad Autonoma San Luis Potosi
Daniel Chavarria, PhD
study director · Universidad Autonoma San Luis Potosi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexketoprofen

Start the discussion